Dayra Therapeutics, a biotechnology startup developing oral macrocyclic peptide medicines for serious diseases, has secured more than $70 million in committed funding. This financing gives the company a strong beginning as it works to advance a therapeutic approach that could make cutting-edge treatments easier to take and potentially more accessible to patients. A major portion of this funding comes from a collaboration with Biogen, which includes a $50 million upfront payment, along with an equity commitment led by Versant Ventures.
A Launch Rooted in Research and Scientific Strategy
Dayra was created through the Frontier Discovery Engine formed by Versant Ventures. The Frontier Discovery Engine supports early research concepts and develops them into operational biotechnology companies capable of pursuing commercial drug programs. Dayra’s foundation is based across Toronto and Montreal, where initial scientific and platform development work began before forming the full company.
Dayra’s leadership includes two key figures. Rami Hannoush, Ph.D., serves as Acting Chief Executive Officer and brings experience in drug discovery, chemical biology, and therapeutic platform development. Roger Palframan, Ph.D., serves as Chief Scientific Officer and has an extensive background in advancing scientific programs in the biotechnology and pharmaceutical sectors.
Macrocyclic Peptides and the Possibility of a New Treatment Format
Dayra is focusing on the development of macrocyclic peptides, a unique type of therapeutic molecule. These molecules sit between two major categories of existing medicine. On one side are small molecules, which are commonly available as oral medications. On the other are biologic drugs, which are highly precise but usually require injections. Macrocyclic peptides offer the potential to combine the precision seen in biologics with the convenience of a pill.
Dayra is working to design macrocyclic therapies through a platform that uses computational modeling alongside biological screening. This approach is intended to help identify oral peptides that can selectively bind to disease-related proteins. The potential benefit of this work is the ability to target biological pathways that are difficult to reach with conventional medicines.
Also Read: Wealthy.in raises ₹130 crore Series B to scale AI-powered platform for mutual fund distributors
Collaboration With Biogen to Advance Drug Candidates
A significant part of Dayra’s launch momentum comes from its newly established partnership with Biogen. Under the terms of this collaboration, Dayra and Biogen will work together to identify and optimize oral macrocyclic peptide drug candidates. The focus of this work will be on high-priority targets in immunology.
Once promising candidates are identified and reach specific stages of development, Biogen will take responsibility for later clinical development activities. These later stages include manufacturing and the possibility of commercializing successful therapies. The collaboration also gives Biogen the option to acquire individual candidate programs. If those options are exercised, they may result in additional future payments tied to progress and development outcomes. These payments depend entirely on successful results and will not occur automatically.
A Strong Entry Into an Emerging Field
Launching with more than $70 million in committed funds and a recognized pharmaceutical partner places Dayra in a strong position among early-stage companies in the same sector. Many new biotechnology companies spend years preparing for this scale of support, which makes Dayra’s starting point noteworthy.
Macrocyclic peptide-based drug development is still considered an emerging area within biotechnology. However, the interest surrounding it continues to grow because of the potential to combine high biological precision with patient-friendly formats. If these therapies can be developed successfully, they may help expand treatment options for multiple disease areas.
Looking Ahead With Measured Optimism
Dayra is still at an early research stage, and the future will depend on scientific results, successful testing and regulatory evaluations. Like many companies working at the discovery phase, progress will take time and must be supported by clear evidence.
Even so, Dayra begins its journey with a defined scientific mission, experienced leadership in Rami Hannoush and Roger Palframan, a funded research platform, and a meaningful partnership with Biogen. These elements together create a promising environment for advancing its therapeutic programs.
A Promising Beginning With Room to Grow
With strong investor commitment and a clear focus on therapeutic innovation, Dayra Therapeutics enters the biotechnology landscape with a solid foundation and forward momentum. If its approach to oral macrocyclic peptides proves effective, it could help shape a future where complex treatments are easier to access and simpler for patients to use.
Also Read: Model ML Raises $75 Million in Series A as AI Reshapes Financial Workflows
